Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2010

View Archived Issues

In vivo data support clinical development of VX15/2503 for MS

OBA-19 offers neuroprotection in model of ischemic stroke

Firategrast suppresses onset of new lesions in relapsing-remitting MS

Telatinib shows promise in patients with cancer of the stomach or gastroesophageal junction

Phase II/III data support teriflunomide monotherapy for relapsing MS

New antagonists of transient receptor potential TRPA1 channel claimed

Theravance announces results from phase I/II TD-1211 studies

Quark Pharma begins phase I QPI-1007 trial for ocular neuroprotection

Risk of abnormal heart rhythm added to Invirase label

Depomed delivers prototype formulation of fixed-dose metformin/canagliflozin

Phase III trial of clofarabine/cytarabine combination in leukemia meets secondary endpoints

Biogen Idec and Genentech amend collaboration agreement on CD20-targeting antibodies

Trastuzumab approved by FDA for HER2-positive metastatic stomach cancer

BioMarin claims new benzoxazole derivatives for dystrophy and cachexia

Phase IIb trial of inhaled liposomal ciprofloxacin meets primary endpoint

Merck & Co. claims new P2X3 receptor antagonists

Enrollment suspended in ACT 5 trial of vernakalant hydrochloride

ACADIA claims new serotonin 5-HT2A receptor modulators

Phase III data presented on oral calcitonin in osteoarthritis

CHMP issues positive opinion on ranibizumab for DME-related vision impairment

PolyMedix plans phase II studies of PMX-60056

Flamel Technologies achieves milestone for extended release interferon beta-1a

Advaxis advances phase II ADXS11-001 trial in cervical dysplasia

FDA requests additional information in complete response letter on lorcaserin NDA

Phase II study of Intercell's IC-43 meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...